A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
Status:
Completed
Trial end date:
2018-05-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacodynamic (PD) effect of CK-2127107 (hereafter referred to
as reldesemtiv) versus placebo on measures of skeletal muscle function or fatigability in
patients with Type II, III, or IV spinal muscular atrophy (SMA).